SVA:CC - Sernova Announces 2022 Annual General Meeting Results
(TheNewswire)
LONDON, ONTARIO – TheNewswire - April 29, 2022 – Sernova Corp.(TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical stage regenerative medicinecompany focused on developing a potential‘functional cure’ for type 1 diabetes (T1D) and other chronicdiseases , is pleased toannounce results from its Annual General Meeting of Shareholders (the“AGM”) held virtually via live audio webcast, on April 28, 2022.Shareholders voted overwhelmingly in favour of all managementresolutions proposed in the Company’s Information Circular.
The following resolutions were proposed and approved atthe AGM:
-
The re-election of the following directors for theensuing year: Frank Holler, James Parsons, Jeffrey Bacha, DeborahBrown, Dr. Mohammad Azab and Dr. Philip Toleikis.
-
The appointment of Davidson Company LLP, as auditorsof the Company until the next annual meeting and the authorization ofthe directors of the Company to fix the remuneration to be paid to theauditors.
“I sincerely appreciate our shareholders ongoingsupport for Sernova. The Board and management are very excited aboutthe immediate and long-term prospects of the Company as we expand ourtherapeutic applications, broaden our capital markets following andexecute on a number of strategic initiatives,” said Dr. PhilipToleikis, President & CEO of Sernova Corp.
Management’s corporate update to shareholders will beavailable on Sernova’s website next week at www.sernova.com .
For further information contact:
Sernova Corp
Christopher Barnes
Tel: (519) 858-5126
christopher.barnes@sernova.com
Corey Davis, Ph.D.
LifeScience Advisors, LLC
Tel: 212-915-2577
ABOUT SERNOVA
Sernova is developing regenerative medicinetherapeutic technologies using a medical device and immune protectedtherapeutic cells (i.e., human donor cells, corrected human cells andstem-cell derived cells) to improve the treatment and quality of lifeof people with chronic metabolic diseases such as insulin- dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com
ABOUT SERNOVA’S CELLPOUCH
The Cell Pouch is a novel, proprietary,scalable, implantable macro-encapsulation device designed for thelong- term survival and function of therapeutic cells. The device isdesigned to incorporate with tissue, forming highly vascularizedtissue chambers for the transplantation and function of therapeuticcells which then release proteins and hormones as required to treatdisease. The device along with therapeutic cells has been shown toprovide long-term safety and efficacy in small and large animal modelsof diabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans.
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements.Forward-looking statements are statements that are not historicalfacts and are generally, but not always, identified by the words“expects”, “plans”, “anticipates”, “believes”,“intends”, “estimates”, “projects”, “potential” andsimilar expressions, or that events or conditions “will”,“would”, “may”, “could” or “should” occur. AlthoughSernova believes the expectations expressed in such forward-lookingstatements are based on reasonable assumptions, such statements arenot guarantees of future performance, and actual results may differmaterially from those in forward-looking statements. Forward-lookingstatements are based on the beliefs, estimates, and opinions ofSernova’s management on the date such statements were made, whichinclude our beliefs about the conduct and outcome of clinical trials.The information disclosed represents results from one patient and maynot be representative of all study patients or of the final studyresults. Sernova expressly disclaims any intention or obligation toupdate or revise any forward-looking statements whether as a result ofnew information, future events or otherwise.
Copyright (c) 2022 TheNewswire - All rights reserved.